Neuromuscular diseases

News

Roche trumpets new fenebrutinib data in relapsing MS

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (M

News

Two of three trials fail, but Sanofi will still file MS drug

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of thr

News

Buoyed by muscular dystrophy data, Avidity raises $345m

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an imp

News

PTC slides on failed Friedreich ataxia study

PTC Therapeutics has cued up no fewer than three clinical trial readouts this quarter that could lead to new regulatory filings – but the latest for vatiquinone in inherited nerve dis

R&D

Health Innovators – Fady Malik and Steve Heitner

In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese

News

Sanofi drops BTK drug tolebrutinib in myasthenia gravis

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso

Roche trumpets new fenebrutinib data in relapsing MS

Two of three trials fail, but Sanofi will still file MS drug

Buoyed by muscular dystrophy data, Avidity raises $345m

PTC slides on failed Friedreich ataxia study

Health Innovators – Fady Malik and Steve Heitner

Sanofi drops BTK drug tolebrutinib in myasthenia gravis

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Neuromuscular diseases

Editor's Picks